5-[([4-(tert-butyl)benzyl]aminothiocarbonyl)amino]methyl-2-[(methylsulfonyl)amino]benzenecarboxylic acid | 401907-32-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[([4-(tert-butyl)benzyl]aminothiocarbonyl)amino]methyl-2-[(methylsulfonyl)amino]benzenecarboxylic acid
• 英文别名: 5-[[(4-Tert-butylphenyl)methylcarbamothioylamino]methyl]-2-(methanesulfonamido)benzoic acid
• CAS: 401907-32-2
• 化学式: C₂₁H₂₇N₃O₄S₂
• 分子量: 449.595
• InChiKey: SSKJYZCANJANCL-UHFFFAOYSA-N

物化性质

• 熔点：
  180 °C
• 沸点：
  626.1±65.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  148
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[([4-(tert-butyl)benzyl]aminothiocarbonyl)amino]methyl-2-[(methylsulfonyl)amino]benzenecarboxylic acid 在 吡啶 、 草酰氯 、 盐酸羟胺 作用下， 以 苯 为溶剂， 反应 2.0h， 生成 5-[3-(4-tert-Butyl-benzyl)-thioureidomethyl]-N-hydroxy-2-methanesulfonylamino-benzamide
  参考文献：
  名称：

  Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:  Structure−Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents

  摘要：

  Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure- activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.

  DOI：

  10.1021/jm0502790
• 作为产物：
  描述：

  2-氨基-5-碘苯甲酸甲酯 在 palladium on activated charcoal 吡啶 、 盐酸 、 lithium hydroxide 、 四(三苯基膦)钯 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 10.5h， 生成 5-[([4-(tert-butyl)benzyl]aminothiocarbonyl)amino]methyl-2-[(methylsulfonyl)amino]benzenecarboxylic acid
  参考文献：
  名称：

  Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:  Structure−Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents

  摘要：

  Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure- activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.

  DOI：

  10.1021/jm0502790

文献信息

• [EN] NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME<br/>[FR] NOUVEAUX DERIVES DE THIOUREA ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
  申请人：PACIFIC CORP

  公开号：WO2002016318A1

  公开（公告）日：2002-02-28

  The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及一种新型硫脲衍生物，作为vanilloid受体（VR）的调节剂以及含有该化合物的制药组合物。作为与vanilloid受体活性相关的疾病，可以列举急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病变、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合症、哮喘或慢性阻塞性肺疾病、皮肤、眼或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病等。本发明提供了用于预防或治疗这些疾病的制药组合物。
• Novel thiourea derivatives and the pharmaceutical compositions containing the same
  申请人：Suh Ger Young

  公开号：US20080064687A1

  公开（公告）日：2008-03-13

  The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及一种新型硫脲衍生物，作为vanilloid受体（VR）的调节剂，并包含相应的药物组合物。作为与vanilloid受体活动相关的疾病，可以列举急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病等。本发明提供了一种用于预防或治疗这些疾病的药物组合物。
• EP1303483A4
  申请人：——

  公开号：EP1303483A4

  公开（公告）日：2004-11-03
• NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：PACIFIC CORPORATION

  公开号：EP1303483B1

  公开（公告）日：2008-04-23
• US8071650B2
  申请人：——

  公开号：US8071650B2

  公开（公告）日：2011-12-06